Literature DB >> 33412217

Impaired attention in patients with adrenal insufficiency - Impact of unphysiological therapy.

Antje K Blacha1, Amir H Rahvar2, Jörg Flitsch2, Iris van de Loo3, Peter Kropp4, Birgit Harbeck5.   

Abstract

Patients with adrenal insufficiency (AI) are treated with glucocorticoid (GC) replacement therapy. Although current GC regimens aim to mimic the physiological circadian rhythm of cortisol secretion, temporary phases of hypo- and hypercortisolism are common undesired effects. Both conditions may lead to impairment in cognitive functioning. At present, little is known about cognitive functioning in patients with AI, especially regarding the effects of dosage and duration of glucocorticoid replacement therapy. There is also little data available comparing the effects of GC therapy on patients with primary (PAI) and secondary (SAI) forms of AI. In this study 40 adults with AI (21 PAI, 19 SAI) substituted with hydrocortisone (HC) and 20 matched healthy controls underwent 10 different neuropsychological tests evaluating memory, executive functioning, attention, psychomotricity and general intellectual ability. Furthermore demographic data, dosage of HC, duration of therapy and co-medication were evaluated. Patients were compared in groups with regard to diagnosis, dosage and duration of therapy. Patients showed worse performance than controls in attention, though patients with PAI and SAI seemed to be equally impaired. There were no limitations in intellectual abilities or memory function. High dosage of HC was found to impair attention, visual-motoric skills and executive functioning while the duration of therapy showed no significant impact on cognitive functions. In conclusion, our study showed that AI patients on HC replacement therapy reveal significant cognitive deficits concerning attention. There was no difference between patients with PAI and SAI. Furthermore, high dosage seems to have a negative impact especially on executive functioning.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenal Insufficiency; Attention; Cognition; Hydrocortisone; PAI; SAI

Year:  2021        PMID: 33412217     DOI: 10.1016/j.steroids.2020.108788

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  6 in total

1.  Assessing recovery of adrenal function in glucocorticoid-treated patients: Our strategy for screening and management.

Authors:  Najat Draoui; Achwak Alla; Nada Derkaoui; Nisrine Bouichrat; Aymane Loukili; Siham Rouf; Hanane Latrech
Journal:  Ann Med Surg (Lond)       Date:  2022-05-07

2.  Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.

Authors:  Clarissa Krekeler; Peter Kropp; Antje Katrin Blacha; Amir-Hossein Rahvar; Birgit Harbeck
Journal:  Endocrine       Date:  2021-02-24       Impact factor: 3.633

Review 3.  Sleep, Cognition and Cortisol in Addison's Disease: A Mechanistic Relationship.

Authors:  Michelle Henry; Kevin Garth Flusk Thomas; Ian Louis Ross
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-27       Impact factor: 5.555

4.  Non-invasive assessment of tissue sodium content in patients with primary adrenal insufficiency.

Authors:  Irina Chifu; Andreas Max Weng; Stephanie Burger-Stritt; Thorsten Alexander Bley; Martin Christa; Herbert Köstler; Stefanie Hahner
Journal:  Eur J Endocrinol       Date:  2022-07-21       Impact factor: 6.558

5.  Impaired quality of life, but not cognition, is linked to a history of chronic hypercortisolism in patients with Cushing's disease in remission.

Authors:  Emilie Pupier; Alicia Santos; Nicole Etchamendy; Aurélie Lavielle; Amandine Ferriere; Aline Marighetto; Eugenia Resmini; Daniela Cota; Susan M Webb; Antoine Tabarin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

6.  Poor quality of life and sleep in patients with adrenal insufficiency-another cause of increased mortality?

Authors:  Antje K Blacha; Peter Kropp; Amir H Rahvar; Jörg Flitsch; Iris van de Loo; Birgit Harbeck
Journal:  Ir J Med Sci       Date:  2021-08-13       Impact factor: 2.089

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.